Miscellaneous hormones and prostaglandins

Singer, 1991, Clinical efficacy of salmon calcitonin in Paget's disease of bone, Calcif. Tissue Int., 49, S7, 10.1007/BF02561369 Hall, 1993, Update on the medical treatment of hypercalcemia of malignancy, Clin. Pharm., 12, 117 Castells, 1979, Therapy of osteogenesis imperfecta with synthetic salmon calcitonin, J. Pediatr., 95, 807, 10.1016/S0022-3476(79)80741-6 Doury, 1980, Le traitement de l'algodystrophie par la thyrocalcitonine (à propos de 60 observations), Rhumatologie, 32, 111 MacIntyre, 1988, Calcitonin for prevention of postmenopausal bone loss, Lancet, 1, 900, 10.1016/S0140-6736(88)91712-6 Gruber, 1984, Long term calcitonin therapy in postmenopausal osteoporosis, Metabolism, 33, 295, 10.1016/0026-0495(84)90187-2 Prelevic, 1992, Postmenopausal osteoporosis: prevention and treatment with calcitonin, Gynecol. Endocrinol., 6, 141, 10.3109/09513599209046398 Wallach, 1993, Calcitonin treatment in osteoporosis, Drug Ther., 23, 61 Wallach, 1993, Calcitonin treatment in osteoporosis, Drug Ther., 23, 67 Wallach, 1993, Calcitonin treatment in osteoporosi, Drug Ther., 23, 73 Levy, 1988, Formation of neutralising antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease, J. Clin. Endocrinol. Metab., 67, 541, 10.1210/jcem-67-3-541 Azria, 1989 Wimalawansa, 1993, Long- and short-term side effects and safety of calcitonin in man: a prospective study, Calcif. Tissue Int., 52, 90, 10.1007/BF00308314 Gennari, 1983, Side effects of synthetic salmon and human calcitonin, Lancet, 1, 594, 10.1016/S0140-6736(83)92846-5 Wuster, 1991, Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers, Eur. J. Clin. Pharmacol., 41, 211, 10.1007/BF00315432 Mallette, 1988, Synthetic human parathyroid hormone 1–34 fragment for diagnostic testing, Ann. Intern. Med., 109, 800, 10.7326/0003-4819-109-10-800 Mallette, 1988, Synthetic human parathyroid hormone (1–34) for the study of pseudohypoparathyroidism, J. Clin. Endocrinol. Metab., 67, 964, 10.1210/jcem-67-5-964 Healy, 1993, Creutzfeldt-Jakob disease after pituitary gonadotrophins, Br. Med. J., 307, 517, 10.1136/bmj.307.6903.517 Griffin, 1991, Transmission of Creutzfeldt-Jakob disease by investigative and therapeutic procedures, Adverse Drug React. Toxicol. Rev., 10, 89 Laron, 1991, Optimum use of growth hormone in children, Drugs, 42, 1, 10.2165/00003495-199142010-00001 Jorgensen, 1990, Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulinlike growth factor-1 and metabolic indices, J. Clin. Endocrinol. Metab., 70, 1616, 10.1210/jcem-70-6-1616 Jorgensen, 1989, Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites, J. Clin. Endocrinol. Metab., 70, 207, 10.1210/jcem-70-1-207 Ross, 1988, The effect of short term treatment with growth hormone and ethinyl estradiol on lower leg growth rate in girls with Turner's syndrome, J. Clin. Endocrinol. Metab., 67, 515, 10.1210/jcem-67-3-515 Price, 1993, Safety and efficacy of human growth hormone treatment in girls with Turner syndrome, Horm. Res., 39, 44, 10.1159/000182768 Rudman, 1990, Effects of human growth hormone in men over 60 years old, New Engl. J. Med., 323, 1, 10.1056/NEJM199007053230101 Rudman, 1991, Effects of human growth hormone on body composition in elderly men, Horm. Res., 36, 73, 10.1159/000182193 Takano, 1986, Clinical experience with somatrem in Japan, Acta Paediatr. Scand., 325, 19, 10.1111/j.1651-2227.1986.tb10358.x Milner, 1986, Clinical experience of somatrem: UK preliminary report, Acta Paediatr. Scand., 325, 24 Bierich, 1986, Treatment of pituitary dwarfism with biosynthetic growth hormone, Acta Paediatr. Scand., 325, 13, 10.1111/j.1651-2227.1986.tb10357.x Westphal, 1986, Experiences of Somatonorm in Sweden, Acta Paediatr. Scand., 325, 41, 10.1111/j.1651-2227.1986.tb10362.x Frasier, 1987, Side effects of pituitary growth hormone therapy, 155 Peter, 1987, Resistance to growth hormone therapy, 164 Walker, 1992, Systemic reaction to human growth hormone treated with acute desensitization, Pediatrics, 90, 108, 10.1542/peds.90.1.108 Fisher, 1988, Leukaemia in patients treated with growth hormone, Lancet, 1, 1159 Shalet, 1993, Leukaemia in children treated with growth hormone, J. Pediatr. Endocrinol., 6, 109, 10.1515/JPEM.1993.6.1.109 Schmid, 1993, Acceleration of epiphyseolysis capitis femoris lenta as a complication of growth hormone therapy in pituitary insufficiency, Klin. Padiatr., 205, 59, 10.1055/s-2007-1025199 Frasier, 1983, Human pituitary growth hormone (hGH) therapy in growth hormone deficiency, Endocr. Rev., 4, 155, 10.1210/edrv-4-2-155 Grunfeld, 1988, The acute effects of human growth hormone administration on thyroid function in normal men, J. Clin. Endocrinol. Metab., 67, 1111, 10.1210/jcem-67-5-1111 Drayer, 1988, Neveneffecten van groeihormoonbehandeling, Tijdschr. Kinder-geneeskd, 56, 40 Walker, 1989, Growth hormone treatment of children with short stature increases insulin secretion but does not impair glucose disposal, J. Clin. Endocrinol. Metab., 69, 253, 10.1210/jcem-69-2-253 Czernichow, 1991, Growth hormone treatment and diabetes: survey of the Kabi Pharmacia International Growth Study, Acta Paediatr. Scand., 379, 104, 10.1111/j.1651-2227.1991.tb12057.x Boissel, 1986, Synthetic growth hormone releasing factor (h-GRF-1-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men, Eur. J. Clin. Pharmacol., 29, 609, 10.1007/BF00635901 Evans, 1985, Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men, J. Clin. Endocrinol. Metab., 61, 846, 10.1210/jcem-61-5-846 Franchimont, 1989, Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women, Acta Endocrinol., 120, 121, 10.1530/acta.0.1200121 Cacabelos, 1988, GHRH-induced GH response in patients with senile dementia of the Alzheimer type, Acta Endocrinol., 117, 295, 10.1530/acta.0.1170295 Butenandt, 1989, Diagnostic value of growth hormone releasing hormone tests in short children, Acta Paediatr. Scand., 349, 93, 10.1111/j.1651-2227.1989.tb17176.x Chatelain, 1987, Growth hormone (GH) response to a single intravenous injection of synthetic GH-releasing hormone in prepubertal children with growth failure, J. Clin. Endocrinol. Metab., 65, 387, 10.1210/jcem-65-3-387 Low, 1988, Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency, J. Clin. Endocrinol. Metab., 66, 611, 10.1210/jcem-66-3-611 Thorner, 1987, The potential of GRF as a therapeutic agent in children with short stature, 246 Thorner, 1985, Development of antibody to growth hormone releasing factor, New Engl. J. Med., 312, 994, 10.1056/NEJM198504113121518 Smith, 1987, The place of intravenous GHRH 1–40 studies in the therapy of growth hormone deficient children with GHRH, Clin. Endocrinol., 27, 97, 10.1111/j.1365-2265.1987.tb00844.x Barkan, 1988, Preoperative treatment of acromegaly with long-acting somatostatin analogue SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate, J. Clin. Endocrinol. Metab., 67, 1040, 10.1210/jcem-67-5-1040 Quabbe, 1989, Dose-re-sponse study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly, J. Clin. Endocrinol. Metab., 68, 873, 10.1210/jcem-68-5-873 Tauber, 1989, Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly, J. Clin. Endocrinol. Metab., 68, 917, 10.1210/jcem-68-5-917 Lamberts, 1987, Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995), Eur. J. Clin. Invest., 17, 354, 10.1111/j.1365-2362.1987.tb02200.x Ezzat, 1992, Octreotide treatment of acromegaly. A randomized, multicenter study, Ann. Intern. Med., 117, 711, 10.7326/0003-4819-117-9-711 Christensen, 1992, Long-term efficacy and tolerability of octreotide treatment in acromegaly, Metabolism, 41, 44, 10.1016/0026-0495(92)90030-E Lamberts, 1993, Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy, Front. Neuroen-docrinol., 14, 27, 10.1006/frne.1993.1002 Fahlbusch, 1993, Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs, J. Endocrinol. Invest., 16, 449, 10.1007/BF03348882 1991 Walker, 1992, Terlipressin vs somatostatin in bleeding esophageal varices: a controlled, double-blind study, Hepatology, 15, 1023, 10.1002/hep.1840150609 Mackie, 1991, Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide, Br. J. Surg., 78, 1338, 10.1002/bjs.1800781123 Manni, 1992, Somatostatin and growth hormone regulation in cancer, Biotherapy, 4, 31, 10.1007/BF02171707 Parmar, 1992, Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer, Clin. Exp. Metastasis, 10, 3, 10.1007/BF00163570 Chanson, 1992, Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide, Metabolism, 41, 62, 10.1016/0026-0495(92)90033-7 Phillips, 1993, Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria: treatment with Sandostatin, Q. J. Med., 86, 233 Davies, 1989, Somatostatin analogues in diabetes mellitus, Diabetic Med., 6, 103, 10.1111/j.1464-5491.1989.tb02096.x Eastman, 1992, A prospective examination of octreotide-induced gall-bladder changes in acromegaly, Clin. Endocrinol., 36, 265, 10.1111/j.1365-2265.1992.tb01442.x Rhodes, 1992, Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment, Scand. J. Gastroenterol., 27, 115, 10.3109/00365529209165429 Sadoul, 1991, Acute pancreatitis following octreotide with-drawal, Am. J. Med., 90, 763, 10.1016/S0002-9343(05)80068-3 Sandow, 1978, Chemistry of the hypothalamic hormones, 149 Colombani, 1982, Upper extremity gangrene secondary to superior mesenteric artery infusion of vasopressin, Digest. Dis. Sci., 27, 367, 10.1007/BF01296759 Thomas, 1985, Cutaneous manifestations of intravenous vasopressin therapy, Am. J. Gastroenterol., 80, 704 Moreno-Sanchez, 1991, Rhabdomyolysis and cutaneous necrosis following intravenous vasopressin infusion, Gastroenterology, 101, 529, 10.1016/0016-5085(91)90034-I Arcidiacono, 1992, Randomised controlled trial with terlipressin in cirrhotic patients with bleeding esophageal varices: effects on precocious rebleeding and mortality rate, Current Ther. Res. Clin. Exp., 52, 186, 10.1016/S0011-393X(05)80451-5 Schmitt, 1987, Ischaemic colitis in a patient treated with glypressin for bleeding oesophageal varices, Hepato-Gastroenterology, 34, 134 Richardson, 1985, Desmopressin, Ann. Intern. Med., 103, 228, 10.7326/0003-4819-103-2-228 Beach, 1992, Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake, Clin. Paediatr., 31, 566, 10.1177/000992289203100913 Nieuwenhuis, 1988, l-Desamino-8-d-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency, Ann. Intern. Med., 108, 65, 10.7326/0003-4819-108-1-65 Kyrle, 1988, IIB von Willebrand's disease: pathogenetic and therapeutic studies, Br. J. Haematol., 69, 55, 10.1111/j.1365-2141.1988.tb07602.x Mannucci, 1992, Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP), Br. J. Haematol., 82, 87, 10.1111/j.1365-2141.1992.tb04598.x Owen, 1992, Oxytocin for the induction or augmentation of labor, Clin. Obstet. Gynaecol., 35, 464, 10.1097/00003081-199209000-00006 Morgan, 1977, Water intoxication and oxytocin infusion, Br. J. Obstet. Gynacol., 84, 6, 10.1111/j.1471-0528.1977.tb12458.x Friedman, 1978, Factors influencing the incidence of neonatal jaundice, Br. Med. J., 1, 1235, 10.1136/bmj.1.6122.1235 Abouleish, 1976, Postpartum hypertension and convulsion after oxytocic drugs, Anesth. Analg., 55, 813, 10.1213/00000539-197611000-00014 Slater, 1985, Anaphylactoid reaction to oxytocin in pregnancy, Anaesthesia, 40, 655, 10.1111/j.1365-2044.1985.tb10944.x Dickinson, 1986, Oxytocin induced second trimester uterine rupture, Aust. New Zealand J. Obstet. Gynaecol., 26, 251, 10.1111/j.1479-828X.1986.tb01580.x Hunter, 1992, Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus, Clin. Pharmacol. Ther., 52, 60, 10.1038/clpt.1992.103 Jackson, 1982, Thyrotropin-releasing hormone, New Engl. J. Med., 306, 145, 10.1056/NEJM198201213060305 Szabolcs, 1989, Thyrotropin-releasing hormone in geriatric patients: intravenous versus intranasal application, Acta Endocrinol., 120, 149, 10.1530/acta.0.1200149 Guiloff, 1987, Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease, J. Neurol. Neurosurg. Psychiatry, 50, 1359, 10.1136/jnnp.50.10.1359 Engel, 1983, Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone, Lancet, 2, 73, 10.1016/S0140-6736(83)90060-0 Dolva, 1983, Side effects of thyrotropin releasing hormone, Br. Med. J., 287, 532, 10.1136/bmj.287.6391.532 Borowski, 1984, Blood pressure response to thyrotropin releasing hormone in euthyroid subjects, J. Clin. Endocrinol. Metab., 38, 197, 10.1210/jcem-58-1-197 Aibiki, 1992, Hypotensive and bradycardiac responses to thyrotropin-releasing hormone in a comatose patient, Clin. Neuropharmacol., 15, 236, 10.1097/00002826-199206000-00004 Barbieri, 1992, Clinical applications of GnRH and its analogues, Trends Endocrinol. Metab., 3, 30, 10.1016/1043-2760(92)90089-J Crowley, 1980, The biological activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men, New Engl. J. Med., 302, 1052, 10.1056/NEJM198005083021903 MacLachlan, 1989, A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization, New Engl. J. Med., 320, 1233, 10.1056/NEJM198905113201902 Mason, 1984, Induction of ovulation with pulsatile luteinising hormone releasing hormone, Br. Med. J., 288, 181, 10.1136/bmj.288.6412.181 Filicori, 1986, Triplet pregnancy after low-dose pulsatile gonadotropin-releasing hormone in polycystic ovarian disease, Am. J. Obstet. Gynaecol., 155, 768, 10.1016/S0002-9378(86)80017-5 Barnes, 1989, Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome, New Engl. J. Med., 320, 559, 10.1056/NEJM198903023200904 Clayton, 1987, Gonadotropin releasing hormone: from physiology to pharmacology, Clin. Endocrinol., 26, 361, 10.1111/j.1365-2265.1987.tb00794.x Donald, 1983, Hypogonadotrophic hypogonadism resistant to hCG and responsive to LHRH: report of a case, Clin. Endocrinol., 18, 385, 10.1111/j.1365-2265.1983.tb00583.x Olsen, 1992, Management of the non-descended testis: doubtful value of luteinizing-hormone-releasing-hormone (LHRH). A double-blind placebo-controlled multicentre study, Int. J. Androl., 15, 135, 10.1111/j.1365-2605.1992.tb01122.x Stanhope, 1988, Growth, growth hormone and steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue, Acta Paediatr. Scand., 77, 525, 10.1111/j.1651-2227.1988.tb10694.x Swaenepoel, 1991, Long-term results of long-acting leutinizing-hormone-releasing hormone agonist in central precocious puberty, Horm. Res., 36, 126, 10.1159/000182145 Tom, 1992, Induction of azoospermia in normal mem with combined Nal−Glu gonadotropin-releasing hormone antagonist and testosterone enanthate, J. Clin. Endocrinol. Metab., 75, 476, 10.1210/jc.75.2.476 Sharifi, 1985, Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate, Urology, 26, 117, 10.1016/0090-4295(85)90042-1 Garnick, 1986, Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial, Urology, 21, 21, 10.1016/S0090-4295(86)80006-1 Schroeder, 1987, Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate, J. Urol., 137, 912, 10.1016/S0022-5347(17)44293-5 Blamey, 1992, Goserelin depot in the treatment of premenopausal advanced breast cancer, Eur. J. Cancer., 28A, 810, 10.1016/0959-8049(92)90120-Q Lopez, 1993, Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer, Cancer, 72, 502, 10.1002/1097-0142(19930715)72:2<502::AID-CNCR2820720228>3.0.CO;2-1 Lind, 1992, A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer, Br. J. Cancer., 65, 621, 10.1038/bjc.1992.126 Peters, 1987, The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia, New. Engl. J. Med., 317, 599, 10.1056/NEJM198709033171004 Van der Spuy, 1992, Management of hyperandrogenism, Contemp. Rev. Obstet. Gynaecol., 4, 90 Shaw, 1992, The role of GnRH analogues in the treatment of endometriosis, Br. J. Obstet. Gynaecol., 99, 9, 10.1111/j.1471-0528.1992.tb13532.x Barbieri, 1993, Gonadotropin releasing hormone agonists: treatment of endometriosis, Clin. Obstet. Gynaecol., 36, 636, 10.1097/00003081-199309000-00019 Mortola, 1993, Applications of gonadotropin releasing hormone analogues in the treatment of premenstrual syndrome, Clin. Obstet. Gunaecol., 36, 753, 10.1097/00003081-199309000-00032 Hussain, 1992, Buserelin in premenstrual syndrome, Gynecol. Endocrinol., 6, 57, 10.3109/09513599209081007 Nakamura, 1993, Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists, Clin. Obstet. Gynecol., 36, 660, 10.1097/00003081-199309000-00022 Bauer, 1992, The effect of a synthetic GnRH analogue on catamenial, epilepsy: a study in ten patients, J. Neurol., 239, 284, 10.1007/BF00810354 Bressler, 1993, Use of clonidine to treat hot flushes secondary to leuprolide or goserelin, Ann. Pharmacother., 27, 182, 10.1177/106002809302700210 Vercellini, 1992, Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment, Gynaecol. Obstet. Invest., 34, 102, 10.1159/000292736 Geisthovel, 1985, Ovarian hyperstimulation due to long term pulsatile intravenous GnRH treatment, Arch. Gynaecol., 236, 255, 10.1007/BF02133944 Rizk, 1992, Ovarian hyperstimulation syndrome after superovulation using GnRh agonists for IVF and related procedures, Hum. Reprod., 7, 320, 10.1093/oxfordjournals.humrep.a137642 Matta, 1988, Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women, Clin. Endocrinol., 29, 45, 10.1111/j.1365-2265.1988.tb00248.x Fogelman, 1992, Gonadotropin-releasing hormone agonists and the skeleton, Fertil. Steril., 57, 715, 10.1016/S0015-0282(16)54948-6 Leather, 1993, The prevention of bone loss in young women treated with GnRH analogues with ‘add-back’ estrogen therapy, Obstet. Gynecol., 81, 104 Surrey, 1993, Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report, Obstet. Gynecol., 81, 581 Chipato, 1991, Pelvic pain complicating LHRH analogue treatment of fibroids, Aust. New Zealand J. Obstet. Gynecol., 31, 383, 10.1111/j.1479-828X.1991.tb02831.x Buhler, 1992, Influence on hormone levels, lipid metabolism and reversibility of endocrinological changes after leuprorelin acetate depot therapy, Clin. Ther., 14, 104 Miller, 1992, Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy, Br. J. Obstet. Gynecol., 99, 37, 10.1111/j.1471-0528.1992.tb13539.x Dusting, 1979, Prostaglandins, their intermediates and precursors: cardiovascular actions and regulatory roles in normal and abnormal circulatory systems, Prog. Cardiovasc. Dis., 21, 405, 10.1016/0033-0620(79)90024-0 Nakano, 1973, General pharmacology of prostaglandins, 23 Hayashi, 1981, Management of severe postpartum hemorrhage due to uterine atony using an analogue of prostaglandin F2α, Obstet. Gynecol., 58, 426 Pulkkinen, 1980, Abortion with sulprostone, a prostaglandin E2 derivative, Int. J. Gynaecol. Obstet., 18, 40, 10.1002/j.1879-3479.1980.tb00238.x Robins, 1980, Alternatives in midtrimester abortion induction, Obstet. Gynecol., 56, 716 Thong, 1992, A retrospective study of 932 second trimester terminations using gemeprost (16,16-dimethyl-trans delta 2 PGE1 methyl ester), Prostaglandins, 44, 65, 10.1016/0090-6980(92)90108-6 Hill, 1991, Management of intra-uterine fetal death with vaginal administration of gemeprost or prostaglandin E2: a random allocation controlled trial, J. Obstet. Gynecol., 11, 422, 10.3109/01443619109013583 Poulsen, 1991, Open randomized comparison of prostaglandin E2 given by intracervical gel or vagitory for preinduction cervical ripening and induction of labor, Acta Obstet. Gynecol. Scand., 70, 549, 10.3109/00016349109007915 Jaschevatzky, 1992, Intrauterine PGF2 alpha infusion for termination of pregnancies with second-trimester rupture of membranes, Obstet. Gynecol., 79, 32 Brandenburg, 1990, Convulsions in epileptic women after administration of prostaglandin E2 derivative, Lancet, 336, 1138, 10.1016/0140-6736(90)92624-Q Ranjan, 1990, Evaluation of sulprostone for second trimester abortions and its effects on liver and kidney functions, Contraception, 25, 175, 10.1016/0010-7824(82)90028-2 Lee, 1974, Cardiovascular-renal effects of prostaglandins. The antihypertensive, natriuretic renal ‘endocrine’ function, Arch. Intern. Med., 133, 56, 10.1001/archinte.1974.00320130058005 Olsson, 1976, Clinical, haemodynamic and metabolic effects of intra arterial infusions of prostaglandin E2 in patients with peripheral vascular disease, 429 Bugiardini, 1985, Myocardial ischaemia induced by prostacyclin and iloprost, Clin. Pharmacol. Ther., 38, 101, 10.1038/clpt.1985.142 Fliers, 1991, A prostaglandin analogue as a probable cause of myocardial infarction in a young woman, Br. Med. J., 302, 416, 10.1136/bmj.302.6773.416-a Lennox, 1991, Cardiac arrest following intramyometrial prostaglandin E2, J. Obstet. Gynecol., 11, 263, 10.3109/01443619109027816 Meyer, 1991, Acute myocardial infarction associated with prostaglandin E2, Am. J. Obstet. Gynecol., 165, 359, 10.1016/0002-9378(91)90092-6 White, 1990, Pulmonary edema after PGE1 infusion, J. Cardiothor. Anesth., 4, 744, 10.1016/S0888-6296(09)90015-1 Smith, 1976, The response of normal and asthmatic subjects to prostaglandin E2 and F2 by different routes and their significance in asthma, 449 Fishburne, 1972, Bronchospasm complicating intravenous prostaglandin E2α for therapeutic abortion, Obstet. Gynecol., 39, 892 Milton, 1976, Modern views on the pathogenesis of fever and the mode of action of antipyretic drugs, J. Pharm. Pharmacol., 28, 393, 10.1111/j.2042-7158.1976.tb04186.x Callen, 1980, Intrapartum and postpartum pyrexia and infection after induction with extra-amniotic prostaglandin E2 in tylose, Br. J. Obstet. Gynaecol., 87, 513, 10.1111/j.1471-0528.1980.tb04588.x Karim, 1978, Prostaglandin-physiological basis of practical applications Lyneham, 1973, Convulsions and electroencephalogram abnormalities after intra-amniotic prostaglandin F2α, Lancet, 2, 1003, 10.1016/S0140-6736(73)91094-5 Sederberg-Olsen, 1983, Prostaglandin-oxytocin induction of mid trimester abortion complicated by grand mal-like seizures, Acta Obstet. Gynaecol. Scand., 62, 79, 10.3109/00016348309155765 Rachmilewitz, 1980, Prostaglandins and diarrhea, Dig. Dis. Sci., 25, 897, 10.1007/BF01308037 Kirton, 1976, Reproduction physiology: prostaglandin associated events, 621 Quinn, 1981, Fetal death following extra amniotic prostaglandin gel. Report of two cases, Br. J. Obstet. Gynaecol., 88, 650, 10.1111/j.1471-0528.1981.tb01224.x Beck, 1982, Hazards of prostaglandin pessaries in postmaturity, Lancet, 2, 161, 10.1016/S0140-6736(82)91131-X Cederqvist, 1980, Rupture of the uterus after midtrimester prostaglandin abortion, J. Reprod. Med., 25, 136 Bromham, 1980, Uterine scar rupture in labour induced with vaginal prostaglandin E2, Lancet, 2, 485, 10.1016/S0140-6736(80)91926-1 Sawyer, 1981, Third-trimester uterine rupture associated with vaginal prostaglandin E2, Am. J. Obstet. Gynecol., 140, 710, 10.1016/0002-9378(81)90212-X Maymon, 1991, Uterine rupture at term pregnancy with the use of intracervical prostglandin E2 gel for induction of labor, Am. J. Obstet. Gynecol., 165, 368, 10.1016/0002-9378(91)90094-8 Maymon, 1992, Third-trimester uterine rupture after prostaglandin E2 use for labor induction, J. Reprod. Med., 37, 449 Momma, 1984, Prostaglandin E1 treatment of ductus-dependent infants with congenital heart disease, Int. Angiol., 3, 33 Parker, 1990, Radiologic case study. Prostaglandin induced cortical hyperostosis, Orthopedics, 13, 240, 10.3928/0147-7447-19900201-16 Matzinger, 1992, Plain film and CT observations in prostaglandin induced bone changes, Pediatr. Radiol., 22, 264, 10.1007/BF02019854 Cohen, 1983, Postoperative ketotic hyperglycaemia during prostaglandin E1 infusion in infancy, Pediatrics, 71, 842, 10.1542/peds.71.5.842 Gryglewski, 1984, Prostacyclin. Pharmacology and clinical trials, Int. Angiol., 3, 89 Katoh, 1992, Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment, J. Pharm. Pharmacol., 44, 442, 10.1111/j.2042-7158.1992.tb03641.x Wigley, 1992, Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis, J. Rheumatol., 19, 1407 Torley, 1991, A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases, Ann. Rheum. Dis., 50, 800, 10.1136/ard.50.11.800 Vowden, 1991, Treatment of digital ischaemia associated with chemotherapy using the prostacyclin analogue iloprost, Eur. J. Vasc. Surg., 5, 593, 10.1016/S0950-821X(05)80351-2 Zusman, 1981, Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent, New Engl. J. Med., 304, 934, 10.1056/NEJM198104163041603 Gruss, 1984, Use of prostaglandins in arterial occlusion diseases, Int. Angiol., 3, 7 Nizankowski, 1985, Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study, Thromb. Res., 37, 21, 10.1016/0049-3848(85)90029-5 Kovasc, 1991, Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism, Am. J. Med., 90, 41, 10.1016/0002-9343(91)90504-Q Gomez-Sanchez, 1991, Different hemodynamic responses between acute and chronic infusion of iloprost (prostacyclin-stable analogue) in severe pulmonary hypertension, Am. Rev. Resp. Dis., 144, 1404, 10.1164/ajrccm/144.6.1404 Darius, 1992, Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty, Agents Actions, 37, 305 Hattori, 1992, A stable prostacyclin analogue, 9B methylcarbacyclin (U-61, 431F), Cardiovasc. Drug Rev., 10, 233, 10.1111/j.1527-3466.1992.tb00248.x Hildebrand, 1991, Oral iloprost in healthy volunteers, Eicosanoids, 4, 149 O'Keefe, 1985, Misoprostol, a synthetic prostaglandin E1 analogue, in the treatment of duodenal ulcers. A double blind, cimetidine-controlled trial, S. Afr. Med. J., 67, 321 Wilson, 1988, Misoprostol and gastroduodenal mucosal protection (cytoprotection), Postgrad. Med. J., 64, 7 Watkinson, 1988, The therapeutic efficacy of misoprostol in peptic ulcer disease, Postgrad. Med. J., 64, 60 Waldhauser, 1988, Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction, J. Urol., 140, 525, 10.1016/S0022-5347(17)41709-5 Chen, 1992, Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1, Br. J. Urol., 69, 404, 10.1111/j.1464-410X.1992.tb15568.x Hemal, 1988, Control of massive vesical hemorrhage due to radiation cystitis with intravesical instillation of (15s)-15-methyl prostaglandin F2 alpha, Int. J. Clin. Pharmacol Ther. Toxicol., 26, 477 Flach, 1988, Topical prostaglandin E2 effects on normal human intraocular pressure, J. Ocul. Pharmacol., 4, 13, 10.1089/jop.1988.4.13 Lee, 1988, The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects, Invest. Ophthalmol. Vis. Sci., 29, 1474